AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi
Citi maintains 'buy' rating on AstraZeneca (AZN) with £186 target, citing efzimfotase alfa trial data. The drug missed primary endpoint but showed improvements in secondary measures. Citi estimates peak sales could reach $4.4bn with broad adult approval, up from $2.3bn. AstraZeneca seeks US approval for patients aged 2+.
How this was made
The 30-second read
Why it matters
The data suggests a sizable market opportunity, potentially driving AZN stock higher ahead of the FDA decision.
Market read
First report of pivotal trial data for a rare‑disease drug, likely to influence AZN valuation.
What to watch
Regulatory timeline and competitive landscape with Strensiq may limit upside.
Background
Citi maintains a buy rating on AZN after presenting new Phase III data at the ASBMR meeting.
Ticker impact
Citi reports new Phase III trial data for AstraZeneca's efzimfotase alfa, highlighting secondary endpoint success and potential $4.4bn peak sales.
potential upside as market prices in higher sales outlook
Citi's buy rating and $4.4bn sales scenario suggest a re‑rating catalyst despite missed primary endpoint.
Market effects
strengthens the rare‑disease biotech sector with a high‑value asset pipeline.
U.S. and European markets may see modest AZN rally.
adds optimism to global pharma pipelines targeting rare bone disorders.
Counterpoint
Missed primary endpoint could dampen enthusiasm; investors may wait for full FDA decision.
Key entities
- companyAstraZeneca PLC
Pharmaceutical company developing efzimfotase alfa.
- analystCiti
Equity research firm providing the buy rating and sales model.
